Start here if you're new
what it is
Olema is a clinical-stage biotech trying to turn one oral breast cancer drug candidate into a real company.
how it gets paid
Last year Olema Pharma made n/a in revenue.
what just happened
The clean takeaway is losses continue, with latest quarterly EPS at -$0.51 and no product revenue to offset it.
At a glance
B balance sheet — gets the job done, barely
75/100 earnings predictability — reasonably predictable
-$2.20 fy2024 eps est
1.7 beta
~$1B market cap
xvary composite: 64/100 — average
What they do
Olema is a clinical-stage biotech trying to turn one oral breast cancer drug candidate into a real company.
Olema’s edge is focus. Its 96-person team has spent the past decade studying the estrogen receptor, which drives about 75% of breast cancer cases. If you back this stock, you are backing deep expertise in one target, not a broad pipeline.
How they make money
n/a
annual revenue
The products that matter
breast cancer drug candidate
palazestrant (OP-1250)
Phase 1b/2 trial · the only clinical asset
it is the company's only Phase 1b/2 asset, which means one program carries essentially all of a ~$1B market cap.
one-asset pipeline
Key numbers
75%
ER-driven cases
The estrogen receptor drives about 75% of breast cancer cases. Plain English: Olema picked a very large target, so what happens in trials matters a lot.
$3M
long-term debt
Long-term debt is just $3 million, or 0% of capital. Plain English: leverage is not the problem here, so what matters is funding research without crushing dilution.
96
employees
Olema has 96 employees. That is a small team for a public biotech, which keeps focus high but leaves little room for mistakes.
$2.20
2024 EPS est.
Estimated 2024 EPS is -$2.20. Plain English: the company is still burning cash, so what you own is time, data, and hope.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 1 — safer than 95% of stocks
- price stability 5 / 100
- long-term debt $3M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for OLMA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The clean takeaway is losses continue, with latest quarterly EPS at -$0.51 and no product revenue to offset it.
Quarterly EPS improved from -$0.70 at the start of 2023 to a range of -$0.55 to -$0.51 across 2024, but the business still has $0M in trailing revenue. This is a clinical program update story dressed up as an earnings report.
$0M
ttm revenue
$0.51
latest quarter eps
$2.20
fy2024 eps est.
the number that mattered
The number that matters is -$2.20, the estimated full-year 2024 EPS, because it tells you Olema is still a cash-burning biotech with no commercial cushion.
source: company filings and consensus, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is palazestrant failing to become a real breast cancer drug. With one Phase 1b/2 asset, $0 in product revenue, and a $1B valuation, there is very little room for a bad readout to hide.
med
single-asset failure
Palazestrant is the only clinical asset on the page. If the data disappoints, there is no second program or approved product to stabilize the story.
Impact: most of the ~$1B market cap is effectively underwriting one experiment.
med
cash burn and future dilution
Cash from operations was -$135M over the last twelve months. The $505M cash pile looks big until you remember there is still no product revenue to refill it.
Impact: at the current burn rate, runway looks like roughly four years before any acceleration in trial costs or capital raising changes the math.
med
external trial dependency
Olema relies on Novartis for ribociclib supply in its trials and on third parties for manufacturing. That means part of the timeline sits outside management's direct control.
Impact: delays, supply issues, or higher costs would not kill the science by themselves, but they can still push out data and strain the cash plan.
med
violent stock moves
This stock has a 1.7 beta, a 5 / 100 price stability score, and a $3–$36 52-week range. Even when the balance sheet looks fine, the share price can behave like a mood swing with a ticker.
Impact: you can be directionally right on the science and still sit through ugly drawdowns before the market agrees with you.
At a $135M annual burn, the $505M cash pile buys time. It does not change the fact that one unapproved drug is carrying a ~$1B valuation.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
palazestrant data cadence
The whole page points back to one Phase 1b/2 asset. Any trial update matters more here than it would at a diversified biotech.
metric
cash runway math
Monitor the quarterly burn against the $505M cash balance. If spending starts outrunning the current roughly four-year runway, dilution risk moves up the list fast.
risk
ribociclib supply dependency
Olema relies on Novartis for a key trial input. When one asset carries the company, even a supply-chain footnote deserves your attention.
trend
volatility versus fundamentals
The stock fell 30% in a four-week stretch in early 2025 and traded between $3 and $36 over 52 weeks. That is biotech sentiment, not smooth compounding.
Analyst rankings
earnings predictability
75 / 100
in human-speak, analysts can model the losses more easily than they can model whether the drug works.
beta
1.7
Beta measures market sensitivity. OLMA has historically moved more than the market, which fits a one-asset biotech with headline risk.
risk rank
1
The balance sheet screens safer than 95% of stocks. The share price does not. Welcome to biotech.
source: institutional data
Institutional activity
institutional ownership data for OLMA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$26
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive